Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21(7):509–28.

Article  CAS  PubMed  Google Scholar 

Tian C, Chen Z. Immune therapy: a new therapy for acute myeloid leukemia. Blood Sci. 2023;5(1):15–24.

Article  PubMed  Google Scholar 

Littman DR. Releasing the brakes on cancer immunotherapy. Cell. 2015;162(6):1186–90.

Article  CAS  PubMed  Google Scholar 

Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, Zheng L. Pan C-x: increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol. 2023;12(1):10.

Article  PubMed  PubMed Central  Google Scholar 

Wang Z, Chen J, Wang M, Zhang L, Yu L. One stone, two birds: the roles of Tim-3 in acute myeloid leukemia. Front Immunol. 2021;12: 618710.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV. Investigators R-: relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, Zhang L, Hu J, Luo P, Zhang J, Liu Z, Peng Y, Liu Z, Tang L, Cheng Q. Immune checkpoint modulators in cancer immunotherapy: Recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111.

Article  PubMed  PubMed Central  Google Scholar 

Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu S, Sun Q, Ren X. Novel strategies for cancer immunotherapy: Counter-immunoediting therapy. J Hematol Oncol. 2023;16(1):38.

Article  PubMed  PubMed Central  Google Scholar 

Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 2020;12:1758835920937612.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Chen Y, Li Z, Huang B, Xu L, Lai J, Lu Y, Zha X, Liu B, Lan Y, Li Y. Single-Cell RNA-Seq of T cells in B-ALL patients reveals an exhausted subset with remarkable heterogeneity. Adv Sci (Weinh). 2021;8(19): e2101447.

Article  PubMed  Google Scholar 

Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11(1):24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, Zeng L, Shi J, Zhang J, Zhou P, Zhang T, Mei Q, Chu Q, Wu K. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023;16(1):94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Song W, Shao C, Shi Y, Han W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell Mol Immunol. 2019;16(1):28–39.

Article  CAS  PubMed  Google Scholar 

Chen C, Liu SM, Chen Y, Han M, Ou Q, Bao H, Xu L, Zhang Y, Zhang JT, Zhong W, Zhou Q, Yang XN, Shao Y, Wu YL, Liu SY, Li Y. Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial. Clin Transl Med. 2022;12(4): e775.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han J, Duan J, Bai H, Wang Y, Wan R, Wang X, Chen S, Tian Y, Wang D, Fei K, Yao Z, Wang S, Lu Z, Wang Z, Wang J. TCR repertoire diversity of peripheral PD-1(+)CD8(+) T Cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer. Cancer Immunol Res. 2020;8(1):146–54.

Article  CAS  PubMed  Google Scholar 

Li CCY. Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological malignancies. Chin J Cancer Res. 2023;35(3):245–51.

PubMed  PubMed Central  Google Scholar 

Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, Hercend T. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171(5):1393–405.

Article  CAS  PubMed  Google Scholar 

Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, Maigret B, Dreano M, Triebel F. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci. 1997;94(11):5744–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang JH, Meijers R, Xiong Y, Liu JH, Sakihama T, Zhang R, Joachimiak A, Reinherz EL. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc Natl Acad Sci. 2001;98(19):10799–804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iouzalen N, Andreae S, Hannier S, Triebel F. LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway. Eur J Immunol. 2001;31(10):2885–91.

Article  CAS  PubMed  Google Scholar 

Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol. 2002;169(10):5392–5.

Article  CAS  PubMed  Google Scholar 

Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y, Chen H. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5–6):176–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keane C, Law SC, Gould C, Birch S, Sabdia MB, Merida Long L, Thillaiyampalam G, Abro E, Tobin JW, Tan X, Xu-Monette ZY, Young KH, Gifford G, Gabreilli S, Stevenson WS, Gill A, Talaulikar D, Jain S, Hernandez A, Halliday SJ, Bird R, Cross D, Hertzberg M, Gandhi MK. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 2020;4(7):1367–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, Du X, Tang L, He F. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 2014;74(13):3418–28.

Article  CAS  PubMed  Google Scholar 

Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616–35.

Article  CAS  PubMed  Google Scholar 

Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176(1–2):334-347 e312.

Article  CAS  PubMed  Google Scholar 

Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021;14(1):147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prigent P, El Mir S, Dreano M, Triebel F. Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol. 1999;29(12):3867–76.

Article  CAS  PubMed  Google Scholar 

Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, Flores M, Li N, Schweighoffer E, Greenberg S, Tybulewicz V, Vignali D, Clynes R. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180(9):5916–26.

Article  CAS  PubMed  Google Scholar 

McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT, DeKruyff RH. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol. 2001;2(12):1109–16.

Article  CAS  PubMed  Google Scholar 

Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ, Kuchroo VK. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102–10.

Article  CAS